1. Home
  2. MAGN vs PRTC Comparison

MAGN vs PRTC Comparison

Compare MAGN & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

N/A

Current Price

$11.43

Market Cap

410.8M

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$16.81

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAGN
PRTC
Founded
1864
2015
Country
United States
United States
Employees
8500
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.8M
464.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MAGN
PRTC
Price
$11.43
$16.81
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
360.0K
3.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.09
N/A
Revenue Next Year
$2.34
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$7.82
$13.30
52 Week High
$20.03
$20.00

Technical Indicators

Market Signals
Indicator
MAGN
PRTC
Relative Strength Index (RSI) 28.43 48.59
Support Level $10.52 $16.51
Resistance Level $12.09 $18.10
Average True Range (ATR) 0.49 0.49
MACD -0.18 -0.08
Stochastic Oscillator 16.50 44.66

Price Performance

Historical Comparison
MAGN
PRTC

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: